Beam Therapeutics
BEAM
24.77
-0.46
-1.82%
Beam Therapeutics
US · BEAM
#2614 by market cap
Listed 2020
24.77
-0.46
-1.82%
Live - 5344 symbols - heartbeat 67s ago
· 2026-10-08 07:00
Pre-market
24.70
-0.28%
After-hours
25.00
+0.91%
Overnight
24.72
-0.20%
- Market cap
- 2.56B
- P/E (TTM)i
- -35.90
- P/Bi
- 2.40
- EPSi
- -0.81
- Div yieldi
- 0.00%
- 52W posi
- 25%
Reader sentiment
Are you bullish or bearish on BEAM?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Good
- Altman Z-Score is 4.96, above the 3.0 "safe zone" threshold.
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 8 years
Latest year +120.01% YoY
Margins
- Operating margin
- -274.57%
- Net margin
- -57.24%
Key ratios & quality
- Altman Z-Scorei
- 4.96
Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 18.00K | 24.00K | 51.84M | 60.92M | 377.71M | 63.52M | 139.74M |
| Gross profit | -- | -- | -- | -- | -- | -- | -- | -- |
| Selling & admin expenses | 11.87M | 20.55M | 29.61M | 57.22M | 87.81M | 116.81M | 111.53M | 113.82M |
| Research & development | 33.87M | 54.62M | 103.18M | 387.09M | 311.59M | 437.38M | 367.56M | 409.62M |
| Operating profit | -45.74M | -75.15M | -132.76M | -392.47M | -338.48M | -176.49M | -415.57M | -383.69M |
| Pretax profit | -116.74M | -78.33M | -194.59M | -370.64M | -260.18M | -131.16M | -376.70M | -79.99M |
| Tax | -- | -- | 0 | 0 | 3.41M | 1.37M | 39.00K | 0 |
| Net profit | -116.74M | -78.33M | -194.59M | -370.64M | -289.09M | -132.53M | -376.74M | -79.99M |
| Basic EPS | -3 | -2 | -4 | -6 | -4 | -2 | -5 | -1 |
| Diluted EPS | -3.34 | -2.01 | -4.19 | -5.77 | -4.13 | -1.72 | -4.58 | -0.81 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | 7.47M | 8.47M | 9.70M | 114.11M | 31.74M | 490.00K |
| Gross profit | -- | -- | -- | -- | -- | -- |
| Selling & admin expenses | 27.94M | 26.86M | 26.74M | 32.28M | 34.43M | 31.95M |
| Research & development | 98.82M | 101.76M | 109.77M | 99.28M | 104.52M | 95.10M |
| Operating profit | -119.29M | -120.15M | -126.81M | -17.45M | -107.22M | -126.55M |
| Pretax profit | -108.33M | -102.14M | -112.73M | 244.30M | -94.32M | -123.13M |
| Tax | -- | 0 | 0 | 0 | -- | -455.00K |
| Net profit | -108.33M | -102.14M | -112.73M | 244.30M | -94.32M | -122.68M |
| Basic EPS | -1 | -1 | -1 | 2 | -1 | -1 |
| Diluted EPS | -1.23 | -1.00 | -1.10 | 2.33 | -0.91 | -1.18 |
Balance sheet
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | 148.28M | 94.54M | 308.32M | 1.27B | 1.09B | 1.21B | 878.15M | 1.27B |
| Cash & ST investments | 146.44M | 91.85M | 299.67M | 965.65M | 1.08B | 1.19B | 850.74M | 1.25B |
| Inventory | -- | -- | -- | -- | -- | -- | -- | -- |
| Total assets | 167.01M | 156.10M | 451.68M | 1.47B | 1.34B | 1.46B | 1.10B | 1.48B |
| Total current liabilities | 25.59M | 29.14M | 102.34M | 213.44M | 223.60M | 205.57M | 182.07M | 96.94M |
| Short-term debt | -- | 4.34M | 4.22M | 7.54M | 10.38M | 12.78M | 13.47M | 14.36M |
| Long-term debt | -- | -- | -- | -- | -- | -- | -- | -- |
| Total liabilities | 32,984,000.00 | 55,154,000.00 | 206,116,000.00 | 647,715,000.00 | 608,240,000.00 | 478,385,000.00 | 370,279,000.00 | 242,819,000.00 |
| Total equity | 134.03M | 100.95M | 245.56M | 826.74M | 733.47M | 981.33M | 733.55M | 1.24B |
| Retained earnings | -124.72M | -203.04M | -397.64M | -768.27M | -1.06B | -1.19B | -1.57B | -1.64B |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 1.25B | 1.18B | 1.10B | 1.27B | 1.27B | 1.18B |
| Cash & ST investments | 1.22B | 1.15B | 1.07B | 1.25B | 1.21B | 1.15B |
| Inventory | -- | -- | -- | -- | -- | -- |
| Total assets | 1.47B | 1.39B | 1.31B | 1.48B | 1.48B | 1.39B |
| Total current liabilities | 141.55M | 174.13M | 182.56M | 96.94M | 74.57M | 80.88M |
| Short-term debt | 13.21M | 12.95M | 12.69M | 14.36M | 14.78M | 15.21M |
| Long-term debt | -- | -- | -- | -- | 100.19M | 100.26M |
| Total liabilities | 343,784,000.00 | 344,344,000.00 | 345,079,000.00 | 242,819,000.00 | 316,360,000.00 | 318,913,000.00 |
| Total equity | 1.12B | 1.05B | 966.00M | 1.24B | 1.16B | 1.07B |
| Retained earnings | -1.68B | -1.78B | -1.89B | -1.64B | -1.74B | -1.86B |
Cash flow
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -20.30M | -72.00M | -95.74M | -66.27M | 22.53M | -149.20M | -347.25M | -345.10M |
| Depreciation & amortization | 650.00K | 3.50M | 4.74M | 7.45M | 22.58M | 20.01M | 21.93M | 22.29M |
| Free cash flow | -33.42M | -84.52M | -112.10M | -113.08M | -26.42M | -182.93M | -356.19M | -360.05M |
| Dividends paid | -- | -- | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | -- | 0 | 319.53M | 757.45M | 108.26M | 269.54M | 0 | 470.51M |
| Ending cash balance | 147.94M | 50.55M | 177.01M | 572.74M | 245.52M | 444.61M | 290.11M | 301.62M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | -103.88M | -76.45M | -81.48M | -83.29M | -128.51M | -66.10M |
| Depreciation & amortization | 5.53M | 5.54M | 5.56M | 5.67M | 5.61M | 5.41M |
| Free cash flow | -106.95M | -79.59M | -86.49M | -87.02M | -130.75M | -68.51M |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | 471.16M | -646.00K | 0 | 0 | 0 | 0 |
| Ending cash balance | 534.52M | 288.77M | 274.62M | 301.62M | 294.98M | 226.54M |
Returns & efficiency
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| ROE %i | -- | -- | -881.16 | -69.13 | -37.06 | -15.46 | -43.94 | -8.11 |
| ROA %i | -136.07 | -56.35 | -64.45 | -38.49 | -20.53 | -9.46 | -29.39 | -6.19 |
| ROIC %i | -- | -- | -230.15 | -56.38 | -30.73 | -12.83 | -36.77 | -6.99 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- | -209.35 | -34.74 |
| EBIT margin %i | -- | -434,105.56 | -553,166.67 | -757.01 | -555.61 | -46.73 | -654.25 | -274.57 |
| FCF / sales %i | -- | -- | -- | -- | -- | -- | -- | -- |
| Current ratioi | 5.79 | 3.24 | 3.01 | 5.96 | 4.89 | 5.89 | 4.82 | 13.09 |
| Quick ratioi | 5.72 | 3.15 | 2.93 | 5.93 | 4.82 | 5.79 | 4.67 | 12.85 |
| Debt / assetsi | 0.00 | 16.35 | 22.19 | 9.65 | 13.34 | 11.83 | 14.62 | 10.41 |
| LT debt / equityi | -- | -- | 39.10 | 16.31 | 22.99 | 16.30 | 20.17 | 11.29 |
| Interest coveragei | -- | -417.86 | -- | -- | -- | -- | -- | -- |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | 1,401.40 | 2,406.01 | 7.00 | 31.88 |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- | -- |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | -38.04 | -41.94 | -47.19 | -8.11 | -5.77 | -8.18 |
| ROA %i | -27.41 | -30.05 | -33.41 | -6.19 | -4.48 | -6.23 |
| ROIC %i | -32.79 | -35.89 | -40.05 | -6.99 | -4.89 | -6.88 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | -677.47 | -739.94 | -837.12 | -274.57 | -226.58 | -242.27 |
| FCF / sales %i | -- | -- | -- | -- | -- | -- |
| Current ratioi | 8.81 | 6.75 | 6.02 | 13.09 | 16.99 | 14.57 |
| Quick ratioi | 8.62 | 6.61 | 5.89 | 12.85 | 16.25 | 14.25 |
| Debt / assetsi | 10.78 | 11.13 | 11.55 | 10.41 | 16.94 | 17.84 |
| LT debt / equityi | 12.90 | 13.55 | 14.36 | 11.29 | 20.27 | 21.75 |
| Interest coveragei | -- | -- | -- | -- | -- | -- |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
Revenue breakdown most recent period
Business
Single segment100.00%
Quote time 2026-10-08 07:00:14 · For reference only, not investment advice and not tailored to your situation.